Annales De Dermatologie Et De Venereologie最新文献

英文中文

Treatment of eosinophilic dermatosis of hematologic malignancy with omalizumab 奥玛珠单抗治疗血液恶性肿瘤嗜酸性皮肤病

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-05-24 DOI: 10.1016/j.annder.2025.103383

E. Hassan, B. Papouin, K. Belhadj, S. Ingen-Housz-Oro

引用次数: 0

French national protocol for diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in adults and children 法国成人和儿童嗜酸性粒细胞增多和全身症状的药物反应诊断和管理国家方案（DRESS）

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-05-20 DOI: 10.1016/j.annder.2025.103381

S. Ingen-Housz-Oro , C. Bernier , H. Assier , F. Tétart , F. Dezoteux , A. Gaillet , B. Bensaid , A. Welfringer-Morin , N. de Prost , D. Staumont-Sallé , M. Tauber , K. Bel Hareth , P. Sanchez , S. Guendouz , C. Hua , S. Fourati , F. Schlemmer , G. Gourier , L. Nakad , C. Hoffmann , V. Descamps

引用次数: 0

Efficacy and safety of intramatricial triamcinolone acetonide injections in nail lichen planus: A retrospective data analysis 甲膜内注射曲安奈德治疗甲扁平苔藓的疗效和安全性：回顾性数据分析

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-05-12 DOI: 10.1016/j.annder.2025.103382

C. Grover, B. Aggawal

Background

Nail lichen planus (NLP) impacts 10–15% of patients with lichen planus and is characterized by discomfort and the potential for permanent damage. Intralesional triamcinolone acetonide (TA) is a first-line treatment; however, comprehensive efficacy data is lacking.

Objective

To evaluate and compare changes in nail lichen planus severity using the Nail Lichen Planus Severity Index (NALSI) in affected fingernails and toenails treated with intramatricial TA (5 mg/ml) injections at 4-weekly and 8-weekly intervals, respectively.

Methods

A retrospective analysis was done for 17 NLP patients treated over 11 years with intramatricial TA (5 mg/ml). Photographic records from each visit were analysed to score disease severity using NALSI. Comparison was made of the percentage of fingernails versus toenails achieving NALSI-50 (50% reduction in NALSI over baseline) at the 3rd and 6th injections.

Results

These 17 patients had 232 nails (68.2%) affected by lichen planus, of which 130 (56%) were fingernails and 102 (44%) were toenails. The mean baseline NALSI of 7.4 ± 2.7 for fingernails, decreased to 6.6 ± 2.7 at the 3rd session, and 4.2 ± 3.2 at 6th session, while for toenails it dropped from 7.02 ± 2.6 to 6.6 ± 2.5 and 5.9 ± 3.0, respectively. By the treatment endpoint (4/8 weeks after fifth injection, respectively, for fingernails and toenails), NALSI-50 reduction was achieved in 40.7% fingernails and 10.8% toenails; while NALSI-75 reduction was achieved in 21.5% fingernails and 4.9% toenails, respectively. Throughout the course of the therapeutic intervention, the proportion of fingernails exhibiting irreversible alterations remained stable at 11.5%. However, a notable increase was observed for toenails, rising from 11.7% at baseline to 13.7% by the conclusion of the study. The adverse effects included pain (23.5% of patients), proximal nail-fold hyperpigmentation and atrophy (23.5%), and subungual hematoma (17.6%).

Conclusion

Intramatricial TA (5 mg/ml) injections are safe and effective in the treatment of NLP, with greater efficacy being noted in fingernails.

背景：10-15%的扁平苔藓患者会发生指甲扁平苔藓（NLP），其特征是不适和永久性损伤的可能性。局部曲安奈德（TA）是一线治疗；然而，缺乏全面的疗效数据。目的采用甲基质内注射（5 mg/ml），每隔4周和8周对患指甲和脚趾甲进行平甲苔严重程度指数（NALSI）评价和比较平甲苔严重程度的变化。方法回顾性分析17例NLP患者在11 年以上接受基质内TA（5 mg/ml）治疗的资料。对每次就诊的照片记录进行分析，使用NALSI评分疾病严重程度。比较第三次和第六次注射时指甲和脚趾甲达到NALSI-50的百分比（NALSI比基线降低50%）。结果17例患者发生扁平苔藓的指甲232根（68.2%），其中指甲130根（56%），趾甲102根（44%）。的平均基线NALSI 7.4±2.7 指甲,下降到6.6 ±2.7 第三会话,和4.2 ±3.2 6会话,而对于脚趾甲从7.02下滑 ± 2.6到6.6 ±  2.5和5.9±3.0 ,分别。到治疗终点（分别在第五次注射后4/8周，指甲和脚趾甲），40.7%的指甲和10.8%的脚趾甲的NALSI-50降低；而指甲和脚趾甲的NALSI-75含量分别降低了21.5%和4.9%。在整个治疗干预过程中，指甲出现不可逆改变的比例稳定在11.5%。然而，观察到脚趾甲的显著增加，从基线的11.7%上升到研究结束时的13.7%。不良反应包括疼痛（23.5%），近端甲襞色素沉着和萎缩（23.5%），趾骨下血肿（17.6%）。结论皮下注射TA（5 mg/ml）治疗NLP安全有效，且对指甲有较好的疗效。

{"title":"Efficacy and safety of intramatricial triamcinolone acetonide injections in nail lichen planus: A retrospective data analysis","authors":"C. Grover, B. Aggawal","doi":"10.1016/j.annder.2025.103382","DOIUrl":"10.1016/j.annder.2025.103382","url":null,"abstract":"<div><h3>Background</h3><div>Nail lichen planus (NLP) impacts 10–15% of patients with lichen planus and is characterized by discomfort and the potential for permanent damage. Intralesional triamcinolone acetonide (TA) is a first-line treatment; however, comprehensive efficacy data is lacking.</div></div><div><h3>Objective</h3><div>To evaluate and compare changes in nail lichen planus severity using the Nail Lichen Planus Severity Index (NALSI) in affected fingernails and toenails treated with intramatricial TA (5 mg/ml) injections at 4-weekly and 8-weekly intervals, respectively.</div></div><div><h3>Methods</h3><div>A retrospective analysis was done for 17 NLP patients treated over 11 years with intramatricial TA (5 mg/ml). Photographic records from each visit were analysed to score disease severity using NALSI. Comparison was made of the percentage of fingernails versus toenails achieving NALSI-50 (50% reduction in NALSI over baseline) at the 3rd and 6th injections.</div></div><div><h3>Results</h3><div>These 17 patients had 232 nails (68.2%) affected by lichen planus, of which 130 (56%) were fingernails and 102 (44%) were toenails. The mean baseline NALSI of 7.4 ± 2.7 for fingernails, decreased to 6.6 ± 2.7 at the 3rd session, and 4.2 ± 3.2 at 6th session, while for toenails it dropped from 7.02 ± 2.6 to 6.6 ± 2.5 and 5.9 ± 3.0, respectively. By the treatment endpoint (4/8 weeks after fifth injection, respectively, for fingernails and toenails), NALSI-50 reduction was achieved in 40.7% fingernails and 10.8% toenails; while NALSI-75 reduction was achieved in 21.5% fingernails and 4.9% toenails, respectively. Throughout the course of the therapeutic intervention, the proportion of fingernails exhibiting irreversible alterations remained stable at 11.5%. However, a notable increase was observed for toenails, rising from 11.7% at baseline to 13.7% by the conclusion of the study. The adverse effects included pain (23.5% of patients), proximal nail-fold hyperpigmentation and atrophy (23.5%), and subungual hematoma (17.6%).</div></div><div><h3>Conclusion</h3><div>Intramatricial TA (5 mg/ml) injections are safe and effective in the treatment of NLP, with greater efficacy being noted in fingernails.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 3","pages":"Article 103382"},"PeriodicalIF":3.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors induced subcutaneous panniculitis-like T-cell lymphoma 免疫检查点抑制剂诱导皮下血管炎样t细胞淋巴瘤

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-05-06 DOI: 10.1016/j.annder.2025.103366

S. Idoudi, A. De Masson, C. Gandon, M. Battistella, S. Caillat-Zucman, S. Pinel, L. Vercellino, F. Jouenne, S. Mourah, B. Baroudjian, C. Lebbe

引用次数: 0

Apremilast: Real-life efficacy and safety in psoriasis limited to the nails 阿普雷米司特：对局限于指甲的牛皮癣的实际疗效和安全性

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-05-03 DOI: 10.1016/j.annder.2025.103377

M. Iorizzo , G. Damiani , S.R. Lipner , A. Pacifico , D. Rigopoulos , A. Sechi , A. Villani , I. Zaraa , B. Richert

Background

Apremilast, an oral phosphodiesterase inhibitor, offers advantages in psoriasis patients in whom biologics are not approved or accepted and where topical treatments have failed. Psoriasis involving the nails, scalp, and genitals is difficult to treat and is associated with a significant decrease in quality of life, requiring an effective treatment.

Objectives

This study aimed to retrospectively assess the efficacy and safety of apremilast 30 mg twice daily in treating psoriasis limited to the nails.

Methods

The charts of 55 adult patients with nail psoriasis treated with apremilast were retrospectively evaluated. Baseline characteristics, including the nail psoriasis severity index (NAPSI) and dermatology life quality index (DLQI), were recorded.

Results

At 6 months of treatment, a statistically significant decrease in both the NAPSI score (44.7 ± 26.9 vs. 19.03 ± 14.2) and the DLQI score (14.5 ± 5 vs. 7.2 ± 4.1) was observed (p < 0.01). None of the patients discontinued the treatment due to side effects.

Conclusions

This study shows improvements in nail psoriasis severity and quality of life with apremilast treatment. Despite potential confounders like psoriatic arthritis, smoking, and manual work, consistent improvements were observed. Apremilast appears to be a valuable treatment option for nail psoriasis. However, further prospective studies are necessary to address the limitations of this retrospective analysis and explore additional endpoints.

apremilast是一种口服磷酸二酯酶抑制剂，在生物制剂未被批准或接受以及局部治疗失败的银屑病患者中具有优势。涉及指甲、头皮和生殖器的牛皮癣很难治疗，并且与生活质量显著下降有关，需要有效的治疗。目的回顾性评价阿普米司特30 mg每日2次治疗局限于指甲的银屑病的疗效和安全性。方法对55例成人甲银屑病阿普米司特治疗的临床资料进行回顾性分析。记录基线特征，包括甲牛皮癣严重程度指数（NAPSI）和皮肤科生活质量指数（DLQI）。 6个月的治疗,于(英格兰中北部)显著降低在NAPSI得分(44.7 ±  26.9和19.03±14.2 )和DLQI得分(14.5 ± 5和7.2 ±4.1 )观察(p & lt; 0.01)。没有一个病人因为副作用而停止治疗。结论本研究显示阿普米司特治疗可改善甲牛皮癣的严重程度和生活质量。尽管存在银屑病关节炎、吸烟和体力劳动等潜在的混杂因素，但观察到持续的改善。阿普拉米司特似乎是治疗指甲牛皮癣的一个有价值的选择。然而，需要进一步的前瞻性研究来解决回顾性分析的局限性并探索其他终点。

{"title":"Apremilast: Real-life efficacy and safety in psoriasis limited to the nails","authors":"M. Iorizzo , G. Damiani , S.R. Lipner , A. Pacifico , D. Rigopoulos , A. Sechi , A. Villani , I. Zaraa , B. Richert","doi":"10.1016/j.annder.2025.103377","DOIUrl":"10.1016/j.annder.2025.103377","url":null,"abstract":"<div><h3>Background</h3><div>Apremilast, an oral phosphodiesterase inhibitor, offers advantages in psoriasis patients in whom biologics are not approved or accepted and where topical treatments have failed. Psoriasis involving the nails, scalp, and genitals is difficult to treat and is associated with a significant decrease in quality of life, requiring an effective treatment.</div></div><div><h3>Objectives</h3><div>This study aimed to retrospectively assess the efficacy and safety of apremilast 30 mg twice daily in treating psoriasis limited to the nails.</div></div><div><h3>Methods</h3><div>The charts of 55 adult patients with nail psoriasis treated with apremilast were retrospectively evaluated. Baseline characteristics, including the nail psoriasis severity index (NAPSI) and dermatology life quality index (DLQI), were recorded.</div></div><div><h3>Results</h3><div>At 6 months of treatment, a statistically significant decrease in both the NAPSI score (44.7 ± 26.9 vs. 19.03 ± 14.2) and the DLQI score (14.5 ± 5 vs. 7.2 ± 4.1) was observed (<em>p</em> < 0.01). None of the patients discontinued the treatment due to side effects.</div></div><div><h3>Conclusions</h3><div>This study shows improvements in nail psoriasis severity and quality of life with apremilast treatment. Despite potential confounders like psoriatic arthritis, smoking, and manual work, consistent improvements were observed. Apremilast appears to be a valuable treatment option for nail psoriasis. However, further prospective studies are necessary to address the limitations of this retrospective analysis and explore additional endpoints.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103377"},"PeriodicalIF":3.1,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143898928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validation of the French version of the hidradenitis suppurativa quality of life (HiSQOL) questionnaire 法文化脓性汗腺炎生活质量（HiSQOL）问卷验证

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-05-03 DOI: 10.1016/j.annder.2025.103379

S. Berros , A.-S. Ficheux , L. Misery , N. Jouan , E. Brenaut

引用次数: 0

Diffuse molluscum contagiosum associated with GATA2 deficiency 弥漫性传染性软疣与GATA2缺乏相关

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-30 DOI: 10.1016/j.annder.2025.103378

C. Bourseau-Quetier, M.-S. Doutre

引用次数: 0

Impact of excess weight on clinical features of psoriasis and efficacy of biologic therapies in children with severe psoriasis: Analysis of data from the BiPe cohorts 超重对严重银屑病患儿牛皮癣临床特征和生物治疗效果的影响：来自BiPe队列的数据分析

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-25 DOI: 10.1016/j.annder.2025.103376

E. Mahé , V. di Lernia , A.-C. Bursztejn , S. Hadj-Rabia , N. Quiles-Tsimaratos , A. Belloni Fortina , I. Neri , A. Lasek , A. Maruani , G. Chaby , J. Gottlieb , S. Barbarot , H. Aubert , C. Droitcourt , S. Mallet , A. Phan , M. Severino-Freire , F. Boralévi , H. Barthélémy , C. Girard , A. Beauchet

Background

Being overweight or obese is associated with both the occurrence of childhood psoriasis and increased severity thereof. We evaluated the impact of being overweight or obese on the clinical features of severe psoriasis in children treated with etanercept, adalimumab, or ustekinumab, and on the therapeutic effectiveness of these treatments using data from the BiPe cohorts.

Patients and methods

Children from the BiPe cohorts with available baseline body mass index data were included. Data from two groups, “normal weight” and “overweight-to-obese” (OTO), and from two OTO subgroups, overweight and obese, were analyzed.

Results

Of the 134 children included, 98 (73.1%) were of normal weight, and 36 (26.9%) were OTO, including 21 (15.7%) overweight and 15 (11.2%) obese children. There were no between-group differences in age at psoriasis onset, family history, clinical features, or severity. Compared to the normal weight group, psoriatic arthritis was more frequent in the OTO group (5.1% versus 16.7% respectively; P = 0.03) and in the overweight and obese subgroups (5.1% versus 14.3% and 20.0%, respectively; P = 0.08). Analysis of PASI scores after 3 months of treatment suggested that biologic therapy efficacy was higher for the OTO group than the normal weight group. Drug continuation rates tended to be lower for the OTO group, particularly for adalimumab (P = 0.0002).

Discussion

OTO status was associated with a higher frequency of psoriatic arthritis in children with psoriasis. Except for lower rates of adalimumab continuation, overall biologic therapy efficacy was similar in the normal and OTO groups. Studies involving larger cohorts are needed to confirm these findings.

背景：超重或肥胖与儿童牛皮癣的发生及其严重程度增加有关。我们使用来自BiPe队列的数据，评估超重或肥胖对依那西普、阿达木单抗或乌斯特金单抗治疗的严重银屑病患儿临床特征的影响，以及这些治疗的治疗效果。患者和方法纳入BiPe队列中具有基线体重指数数据的儿童。我们分析了“正常体重”和“超重至肥胖”（OTO）两组以及OTO两个亚组（超重和肥胖）的数据。结果134例患儿中体重正常98例（73.1%），超正常36例（26.9%），其中超重21例（15.7%），肥胖15例（11.2%）。在银屑病发病年龄、家族史、临床特征或严重程度方面，组间无差异。与正常体重组相比，OTO组的银屑病关节炎发病率更高(分别为5.1%和16.7%；P = 0.03)和超重和肥胖亚组(分别为5.1%对14.3%和20.0%； = 0.08页)。治疗3 个月后PASI评分分析表明，OTO组的生物治疗效果高于正常体重组。OTO组的药物延续率往往较低，特别是阿达木单抗（P = 0.0002）。oto状态与银屑病患儿患银屑病关节炎的较高频率相关。除了阿达木单抗延续率较低外，正常组和OTO组的总体生物治疗效果相似。需要更大规模的研究来证实这些发现。

{"title":"Impact of excess weight on clinical features of psoriasis and efficacy of biologic therapies in children with severe psoriasis: Analysis of data from the BiPe cohorts","authors":"E. Mahé , V. di Lernia , A.-C. Bursztejn , S. Hadj-Rabia , N. Quiles-Tsimaratos , A. Belloni Fortina , I. Neri , A. Lasek , A. Maruani , G. Chaby , J. Gottlieb , S. Barbarot , H. Aubert , C. Droitcourt , S. Mallet , A. Phan , M. Severino-Freire , F. Boralévi , H. Barthélémy , C. Girard , A. Beauchet","doi":"10.1016/j.annder.2025.103376","DOIUrl":"10.1016/j.annder.2025.103376","url":null,"abstract":"<div><h3>Background</h3><div>Being overweight or obese is associated with both the occurrence of childhood psoriasis and increased severity thereof. We evaluated the impact of being overweight or obese on the clinical features of severe psoriasis in children treated with etanercept, adalimumab, or ustekinumab, and on the therapeutic effectiveness of these treatments using data from the BiPe cohorts.</div></div><div><h3>Patients and methods</h3><div>Children from the BiPe cohorts with available baseline body mass index data were included. Data from two groups, “normal weight” and “overweight-to-obese” (OTO), and from two OTO subgroups, overweight and obese, were analyzed.</div></div><div><h3>Results</h3><div>Of the 134 children included, 98 (73.1%) were of normal weight, and 36 (26.9%) were OTO, including 21 (15.7%) overweight and 15 (11.2%) obese children. There were no between-group differences in age at psoriasis onset, family history, clinical features, or severity. Compared to the normal weight group, psoriatic arthritis was more frequent in the OTO group (5.1% versus 16.7% respectively; <em>P</em> = 0.03) and in the overweight and obese subgroups (5.1% versus 14.3% and 20.0%, respectively; <em>P</em> = 0.08). Analysis of PASI scores after 3 months of treatment suggested that biologic therapy efficacy was higher for the OTO group than the normal weight group. Drug continuation rates tended to be lower for the OTO group, particularly for adalimumab (<em>P</em> = 0.0002).</div></div><div><h3>Discussion</h3><div>OTO status was associated with a higher frequency of psoriatic arthritis in children with psoriasis. Except for lower rates of adalimumab continuation, overall biologic therapy efficacy was similar in the normal and OTO groups. Studies involving larger cohorts are needed to confirm these findings.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103376"},"PeriodicalIF":3.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bullous pemphigoid following radiotherapy combined with ipilimumab-nivolumab therapy 放疗联合伊匹单抗-纳武单抗治疗后的大疱性类天疱疮

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-22 DOI: 10.1016/j.annder.2025.103367

A. Pankakoski, J. Panelius, N. Kluger

引用次数: 0

Asynchronous radiation recall dermatitis on two different irradiated areas 非同步辐射可引起两个不同照射区域的皮炎

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-22 DOI: 10.1016/j.annder.2025.103372

I. Berkaoui, N. Litrowski, C. Boulard

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Annales De Dermatologie Et De Venereologie

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀